Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
Authors:
- R ChenRCR Chen
- CV181-039 InvestigatorsCICV181-039 Investigators
- 6 May 2009
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (6) , 611-622
Abstract
Aim: The study aim was to evaluate the efficacy and safety of initial combination therapy with saxagliptin + metformin vs. saxagliptin or metformin monotherapy in treatment‐naïve patients with type 2 diabetes (T2D) and inadequate glycaemic control. Methods: In this multicentre, randomized, double‐blind, active‐controlled phase 3 trial, 1306 treatment‐naïve patients with T2D ≥18 to ≤77 years, glycosylated haemoglobin (HbA1c) ≥8 to ≤12%, fasting C‐peptide concentration ≥1.0 ng/ml, body mass index ≤40 kg/m 2 were randomized to receive saxagliptin 5 mg + metformin 500 mg, saxagliptin 10 mg + metformin 500 mg, saxagliptin 10 mg + placebo or metformin 500 mg + placebo for 24 weeks. From weeks 1–5, metformin was uptitrated in 500‐mg/day increments to 2000 mg/day maximum in the saxagliptin 5 mg + metformin, saxagliptin 10 mg + metformin and metformin + placebo treatment groups. The main outcome measure was HbA1c change from baseline to week 24. Selected secondary outcomes included change from baseline to week 24 in fasting plasma glucose (FPG), proportion of patients achieving HbA1c Results: At 24 weeks, saxagliptin 5 mg + metformin and saxagliptin 10 mg + metformin demonstrated statistically significant adjusted mean decreases vs. saxagliptin 10 mg and metformin monotherapies in HbA1c (−2.5 and −2.5% vs. −1.7 and −2.0%, all p < 0.0001 vs. monotherapy) and FPG (−60 and −62 mg/dl vs. −31 and −47 mg/dl, both p < 0.0001 vs. saxagliptin 10 mg; p = 0.0002 saxagliptin 5 mg + metformin vs. metformin; p < 0.0001 saxagliptin 10 mg + metformin vs. metformin). Proportion of patients achieving an HbA1c Conclusion: Saxagliptin + metformin as initial therapy led to statistically significant improvements compared with either treatment alone across key glycaemic parameters with a tolerability profile similar to the monotherapy components.Keywords
This publication has 25 references indexed in Scilit:
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Translating the A1C Assay Into Estimated Average Glucose ValuesDiabetes Care, 2008
- Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*Diabetes, Obesity and Metabolism, 2008
- DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetesFrontiers in Bioscience-Landmark, 2008
- Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 DiabetesDiabetes Care, 2007
- Oral antidiabetic agents in type 2 diabetesCurrent Medical Research and Opinion, 2007
- Standards of Medical Care in Diabetes—2007Diabetes Care, 2007
- Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998